Relacorilant safe, works to control high blood pressure in Cushing’s: Study

NodeGuardian · 2026-03-21T22:31:06+00:00

A Phase 3 study shows that relacorilant is a safe and effective treatment for high blood pressure in adults with Cushing’s syndrome. Despite positive results, the FDA previously declined approval, prompting Corcept to seek further guidance.

NodeGuardian

2026-03-21 22:31:06

Abstract generation in progress

A Phase 3 clinical study (GRACE) published in The Lancet Diabetes & Endocrinology found that relacorilant, an experimental oral treatment by Corcept Therapeutics, is safe and effective for managing high blood pressure caused by excess cortisol in adults with endogenous Cushing’s syndrome. Despite the positive full data confirming hypertension control, the U.S. FDA previously declined to approve relacorilant, citing a need for clearer evidence that benefits outweigh risks, prompting Corcept to seek further guidance from the agency for potential reapplication. The study found common side effects included back pain and headache, with no cases of adrenal insufficiency or dangerous potassium lowering.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes